MI HB4890

Creates an insulin production program within the Michigan Strategic Fund to establish state-owned insulin facilities operated by private sector contractors for manufacturing and distributing generic or biosimilar insulin, particularly long-acting and rapid-acting insulin.

Authorizes the fund to provide grants up to $150,000,000 to a private sector contractor for construction or renovation of insulin production and distribution facilities, with state ownership of real property required.

Requires written agreements with private sector contractors for at least 15 years, including pricing transparency, sales without pharmacy benefit manager rebates, Michigan-branded insulin availability, and repayment provisions for breaches or failure to meet milestones.

Establishes the insulin production fund in the state treasury and permits fund expenditures for program administration, contractor grants, insulin purchases, and related activities to support affordable insulin access for Michigan residents.

Authorizes the fund to issue requests for proposals annually to temporary private sector contractors to purchase insulin while the production facility is being completed, with requirements for state-branded insulin and no rebates to pharmacy benefit managers.